Thorne Jennifer E, Woreta Fasika, Kedhar Sanjay R, Dunn James P, Jabs Douglas A
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Am J Ophthalmol. 2007 May;143(5):840-846. doi: 10.1016/j.ajo.2007.01.033. Epub 2007 Mar 23.
To estimate the incidences of ocular complications and vision loss in patients with juvenile idiopathic arthritis (JIA)-associated uveitis, to describe risk factors for vision loss, and to describe the association between therapy and complications and vision loss.
Retrospective cohort study.
setting: Single-center, academic practice. study population: A total of 75 patients with JIA-associated uveitis evaluated between July 1984 and August 2005. procedures: Clinical data on these patients were analyzed. outcome measures: Occurrence of ocular complications and visions of 20/50 or worse and 20/200 or worse.
Over a median follow-up of three years, the incidence of any ocular complication was 0.33/eye-year (EY). Rates of vision loss to 20/50 or worse and 20/200 or worse were 0.10/EY and 0.08/EY, respectively. Risk factors at presentation for incident vision loss included presence of posterior synechiae, anterior chamber flare > or = 1+, and abnormal intraocular pressure (IOP). During follow-up, ocular inflammation > or = 0.5+ cells was associated with an increased risk of visual impairment (relative risk [RR] = 2.02, P = .006) and of blindness (RR = 2.99, P = .03). Immunosuppressive drug therapy reduced the risk of hypotony by 74% (P = .002), epiretinal membrane formation by 86% (P = .05), and blindness in the better eye by 60% (P = .04).
Incident vision loss and complications were common. Presence of posterior synechiae, anterior chamber flare > or = 1+, and abnormal IOP at presentation were associated with vision loss during follow-up. Use of immunosuppressive drugs reduced the risk of some ocular complications and of blindness in the better-seeing eye.
评估青少年特发性关节炎(JIA)相关葡萄膜炎患者眼部并发症及视力丧失的发生率,描述视力丧失的危险因素,并阐述治疗与并发症及视力丧失之间的关联。
回顾性队列研究。
地点:单中心学术机构。研究人群:1984年7月至2005年8月期间共75例JIA相关葡萄膜炎患者。程序:分析这些患者的临床资料。观察指标:眼部并发症的发生情况以及视力降至20/50及以下和20/200及以下的情况。
中位随访三年期间,任何眼部并发症的发生率为0.33/眼年(EY)。视力降至20/50及以下和20/200及以下的发生率分别为0.10/EY和0.08/EY。出现视力丧失的危险因素包括存在后粘连、前房闪辉≥1+以及眼压(IOP)异常。随访期间,眼部炎症≥0.5+细胞与视力损害风险增加相关(相对风险[RR]=2.02,P=0.006)以及失明风险增加相关(RR=2.99,P=0.03)。免疫抑制药物治疗使低眼压风险降低74%(P=0.002),视网膜前膜形成风险降低86%(P=0.05),较好眼失明风险降低60%(P=0.04)。
视力丧失及并发症很常见。出现后粘连、前房闪辉≥1+以及眼压异常与随访期间视力丧失相关。使用免疫抑制药物可降低某些眼部并发症及较好眼失明的风险。